Pierre van de Weghe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pierre van de Weghe has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Jacques Eustache
9 shared publicationsPhilippe Uriac
Equipe Produits Naturels, Synthèses et Chimie Médicinale (PNSCM), UMR CNRS 6226, Université de Rennes 1, 2, Avenue du Prof. L. Bernard, 35043 Rennes Cedex, France
9 shared publicationsJacqueline Collin
7 shared publicationsMickael Jean
7 shared publicationsBéatrice Legouin
Equipe Produits Naturels, Synthèses et Chimie Médicinale (PNSCM), UMR CNRS 6226, Université de Rennes 1, 2, Avenue du Prof. L. Bernard, 35043 Rennes Cedex, France
6 shared publications- Jacques Eustache
Laboratoire de Chimie Organique et Bioorganique associé au CNRS, Université de Haute-Alsace, Ecole Nationale Supérieure de Chimie de Mulhouse, 3, rue Alfred Werner, F-68093 Mulhouse Cedex, France
6 shared publications
Latest Publications
- 1 September 2017
- Published by Elsevier in Fitoterapia
- Vol. 121, 164-169
Antibacterial activities of natural lichen compounds against Streptococcus gordonii and Porphyromonas gingivalis
- 1 September 2017
- Published by Elsevier in Fitoterapia
- Vol. 121, 164-169
Antibacterial activities of natural lichen compounds against Streptococcus gordonii and Porphyromonas gingivalis
- 1 November 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (22) , 5823-5833
Design, synthesis and biological evaluation of potential antibacterial butyrolactones
- 1 November 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (22) , 5823-5833
Design, synthesis and biological evaluation of potential antibacterial butyrolactones
- 9 August 2016
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 81 (17) , 7760-7770
Modular Synthesis of Arylacetic Acid Esters, Thioesters, and Amides from Aryl Ethers via Rh(II)-Catalyzed Diazo Arylation
One-pot formation of arylacetic acid esters, thioesters and amides via Rh(II)-catalyzed arylation of a Meldrum’s acid-derived diazo reagent with electron-rich arenes is described. The methodology was used to efficiently synthesize an anticancer compound.
- 9 August 2016
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 81 (17) , 7760-7770
Modular Synthesis of Arylacetic Acid Esters, Thioesters, and Amides from Aryl Ethers via Rh(II)-Catalyzed Diazo Arylation
One-pot formation of arylacetic acid esters, thioesters and amides via Rh(II)-catalyzed arylation of a Meldrum’s acid-derived diazo reagent with electron-rich arenes is described. The methodology was used to efficiently synthesize an anticancer compound.
- 9 August 2016
- Published by Bentham Science Publishers Ltd. in Recent Patents on Anti-Cancer Drug Discovery
- Vol. 11 (3) , 283-296
Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Background: Constitutive activation of the PI3K/mTOR signaling pathway is observed in most, if not all, breast cancers. Accordingly, many PI3K and/or mTOR inhibitors have entered clinical trials, and completed studies should soon reveal the efficacy of these new drug families in the treatment of cancer patients. Objective: We present the PI3K/Akt/mTOR signaling pathway and the structure and the anti-tumor efficiency of some mTOR inhibitors such as rapalogues and competitive inhibitors, which have entered clinical trials. We also discuss some of the clinical trial results associated with these molecules mainly focusing on studies performed on relapsing breast cancer patients - but not only. Results: Most of the clinical trials with PI3K/mTOR inhibitors alone or in combination with chemotherapies were performed in heavily pre-treated patients and revealed non-negligible amounts of partial responses and long-term stable disease for these patients. Therefore, these compounds seem to prevent tumor growth and survival of cancer cells in Human, representing a new range of anti-tumor drugs that can be utilized not only as first-line treatments but as second- and third-line agents for patients who relapse. Conclusion: Drugs inhibiting the PI3K/mTOR signaling pathway may represent tailored anti-tumor agents, paving the way for their clinical application in different tumor types.
- 9 August 2016
- Published by Bentham Science Publishers Ltd. in Recent Patents on Anti-Cancer Drug Discovery
- Vol. 11 (3) , 283-296
Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Background: Constitutive activation of the PI3K/mTOR signaling pathway is observed in most, if not all, breast cancers. Accordingly, many PI3K and/or mTOR inhibitors have entered clinical trials, and completed studies should soon reveal the efficacy of these new drug families in the treatment of cancer patients. Objective: We present the PI3K/Akt/mTOR signaling pathway and the structure and the anti-tumor efficiency of some mTOR inhibitors such as rapalogues and competitive inhibitors, which have entered clinical trials. We also discuss some of the clinical trial results associated with these molecules mainly focusing on studies performed on relapsing breast cancer patients - but not only. Results: Most of the clinical trials with PI3K/mTOR inhibitors alone or in combination with chemotherapies were performed in heavily pre-treated patients and revealed non-negligible amounts of partial responses and long-term stable disease for these patients. Therefore, these compounds seem to prevent tumor growth and survival of cancer cells in Human, representing a new range of anti-tumor drugs that can be utilized not only as first-line treatments but as second- and third-line agents for patients who relapse. Conclusion: Drugs inhibiting the PI3K/mTOR signaling pathway may represent tailored anti-tumor agents, paving the way for their clinical application in different tumor types.
- Open Access
- 1 March 2016
- Published by Elsevier in Catalysis Communications
- Vol. 78, 52-54
Cyclopentadienyliron dicarbonyl dimer: A simple tool for the hydrosilylation of aldehydes and ketones under air
- 1 March 2016
- Published by Elsevier in Catalysis Communications
- Vol. 78, 52-54
Open AccessCyclopentadienyliron dicarbonyl dimer: A simple tool for the hydrosilylation of aldehydes and ketones under air
- 13 January 2016
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 81 (3) , 849-859
Synergistic Effect of the TiCl4/p-TsOH Promoter System on the Aza-Prins Cyclization
A novel aza-Prins cyclization promoted by a synergistic combination between a Lewis acid and a Brønsted acid to efficiently afford piperidines is described. Contrary to what has been previously reported in the literature, the generality of the reaction employing N-alkyl, N-aryl and non-protected homoallylamine has been demonstrated. The reaction is highly diastereoselective depending on the homoallylic amine used, N-PMP homoallyl amine leading preferentially to the trans diastereomer, free homoallylamine affording the deprotected piperidine as single cis diastereomer.
- 13 January 2016
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 81 (3) , 849-859
Synergistic Effect of the TiCl4/p-TsOH Promoter System on the Aza-Prins Cyclization
A novel aza-Prins cyclization promoted by a synergistic combination between a Lewis acid and a Brønsted acid to efficiently afford piperidines is described. Contrary to what has been previously reported in the literature, the generality of the reaction employing N-alkyl, N-aryl and non-protected homoallylamine has been demonstrated. The reaction is highly diastereoselective depending on the homoallylic amine used, N-PMP homoallyl amine leading preferentially to the trans diastereomer, free homoallylamine affording the deprotected piperidine as single cis diastereomer.
- 3 August 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (16) , 6559-6573
A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
- 3 August 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (16) , 6559-6573
A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
- 30 July 2015
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 13 (35) , 9168-9175
Strategy of total synthesis based on the use of Rh-catalyzed stereoselective 1,4-addition
In 1998, Hayashi and Miyaura reported the first asymmetric conjugate addition of aryl- and alkenyl-boronic acids to α,β-unsaturated ketones using chiral rhodium complexes as catalysts.
- 30 July 2015
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 13 (35) , 9168-9175
Strategy of total synthesis based on the use of Rh-catalyzed stereoselective 1,4-addition
In 1998, Hayashi and Miyaura reported the first asymmetric conjugate addition of aryl- and alkenyl-boronic acids to α,β-unsaturated ketones using chiral rhodium complexes as catalysts.
- 1 November 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (22) , 5216-5218
Synthesis of new bioisosteric hemiasterlin analogues with extremely high cytotoxicity
- 1 November 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (22) , 5216-5218
Synthesis of new bioisosteric hemiasterlin analogues with extremely high cytotoxicity
- 22 May 2014
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 50 (56) , 7495-7498
Enantioselective Prins cyclization: BINOL-derived phosphoric acid and CuCl synergistic catalysis
The first catalytic enantioselective Prins cyclization is disclosed. The reaction is catalyzed by the combination of a chiral BINOL-derived bis-phosphoric acid and CuCl. The process consists of a tandem Prins/Friedel–Crafts cyclization that affords the hexahydro-1H-benzo[f]isochromenes products with three new contiguous stereogenic centers in high yields, and good enantio- and excellent diastereoselectivities.
- 22 May 2014
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 50 (56) , 7495-7498
Enantioselective Prins cyclization: BINOL-derived phosphoric acid and CuCl synergistic catalysis
The first catalytic enantioselective Prins cyclization is disclosed. The reaction is catalyzed by the combination of a chiral BINOL-derived bis-phosphoric acid and CuCl. The process consists of a tandem Prins/Friedel–Crafts cyclization that affords the hexahydro-1H-benzo[f]isochromenes products with three new contiguous stereogenic centers in high yields, and good enantio- and excellent diastereoselectivities.